229 related articles for article (PubMed ID: 23932952)
1. Treating osteoporosis by targeting parathyroid hormone to bone.
Ponnapakkam T; Katikaneni R; Sakon J; Stratford R; Gensure RC
Drug Discov Today; 2014 Mar; 19(3):204-8. PubMed ID: 23932952
[TBL] [Abstract][Full Text] [Related]
2. Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice.
Ponnapakkam T; Katikaneni R; Miller E; Ponnapakkam A; Hirofumi S; Miyata S; Suva LJ; Sakon J; Matsushita O; Gensure RC
Calcif Tissue Int; 2011 Jun; 88(6):511-20. PubMed ID: 21512758
[TBL] [Abstract][Full Text] [Related]
3. Bone-targeting parathyroid hormone conjugates outperform unmodified PTH in the anabolic treatment of osteoporosis in rats.
Yang Y; Aghazadeh-Habashi A; Panahifar A; Wu Y; Bhandari KH; Doschak MR
Drug Deliv Transl Res; 2017 Aug; 7(4):482-496. PubMed ID: 28721611
[TBL] [Abstract][Full Text] [Related]
4. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone.
Kostenuik PJ; Ferrari S; Pierroz D; Bouxsein M; Morony S; Warmington KS; Adamu S; Geng Z; Grisanti M; Shalhoub V; Martin S; Biddlecome G; Shimamoto G; Boone T; Shen V; Lacey D
J Bone Miner Res; 2007 Oct; 22(10):1534-47. PubMed ID: 17576164
[TBL] [Abstract][Full Text] [Related]
5. A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice.
Ponnapakkam T; Katikaneni R; Suda H; Miyata S; Matsushita O; Sakon J; Gensure RC
Calcif Tissue Int; 2012 Sep; 91(3):196-203. PubMed ID: 22806683
[TBL] [Abstract][Full Text] [Related]
6. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials.
Shen L; Xie X; Su Y; Luo C; Zhang C; Zeng B
PLoS One; 2011; 6(10):e26267. PubMed ID: 22022584
[TBL] [Abstract][Full Text] [Related]
7. ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis.
Nemeth EF
IDrugs; 2008 Nov; 11(11):827-40. PubMed ID: 18988128
[TBL] [Abstract][Full Text] [Related]
8. Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.
Tay D; Cremers S; Bilezikian JP
Br J Clin Pharmacol; 2018 Feb; 84(2):252-267. PubMed ID: 29049872
[TBL] [Abstract][Full Text] [Related]
9. The use of PTH in the treatment of osteoporosis.
Borba VZ; Mañas NC
Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):213-9. PubMed ID: 20485911
[TBL] [Abstract][Full Text] [Related]
10. [Anabolic treatment for osteoporosis: PTH treatment].
Kaji H; Sugimoto T
Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
[TBL] [Abstract][Full Text] [Related]
11. Anabolic effects of PTH and the 'anabolic window'.
Pazianas M
Trends Endocrinol Metab; 2015 Mar; 26(3):111-3. PubMed ID: 25662368
[TBL] [Abstract][Full Text] [Related]
12. Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy.
Sinha P; Aarnisalo P; Chubb R; Poulton IJ; Guo J; Nachtrab G; Kimura T; Swami S; Saeed H; Chen M; Weinstein LS; Schipani E; Sims NA; Kronenberg HM; Wu JY
J Biol Chem; 2016 Jan; 291(4):1631-1642. PubMed ID: 26598522
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans.
Aslan D; Andersen MD; Gede LB; de Franca TK; Jørgensen SR; Schwarz P; Jørgensen NR
Scand J Clin Lab Invest; 2012 Feb; 72(1):14-22. PubMed ID: 22085136
[TBL] [Abstract][Full Text] [Related]
14. Advances in Controlled Drug Delivery for Treatment of Osteoporosis.
Asafo-Adjei TA; Chen AJ; Najarzadeh A; Puleo DA
Curr Osteoporos Rep; 2016 Oct; 14(5):226-38. PubMed ID: 27502334
[TBL] [Abstract][Full Text] [Related]
15. Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism.
Shao Y; Hernandez-Buquer S; Childress P; Stayrook KR; Alvarez MB; Davis H; Plotkin LI; He Y; Condon KW; Burr DB; Warden SJ; Robling AG; Yang FC; Wek RC; Allen MR; Bidwell JP
Endocrinology; 2017 Sep; 158(9):2722-2740. PubMed ID: 28637206
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
Hodsman AB; Bauer DC; Dempster DW; Dian L; Hanley DA; Harris ST; Kendler DL; McClung MR; Miller PD; Olszynski WP; Orwoll E; Yuen CK
Endocr Rev; 2005 Aug; 26(5):688-703. PubMed ID: 15769903
[TBL] [Abstract][Full Text] [Related]
17. Delivery of parathyroid hormone for the treatment of osteoporosis.
Morley P
Expert Opin Drug Deliv; 2005 Nov; 2(6):993-1002. PubMed ID: 16296804
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyapatite nanorods loaded with parathyroid hormone (PTH) synergistically enhance the net formative effect of PTH anabolic therapy.
Dave JR; Dewle AM; Mhaske ST; Phulpagar PT; Mathe VL; More SE; Khan AA; Murthy AVR; Datar SS; Jog AJ; Page M; Tomar GB
Nanomedicine; 2019 Jan; 15(1):218-230. PubMed ID: 30343014
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone in the treatment of osteoporosis.
Fujita T
BioDrugs; 2001; 15(11):721-8. PubMed ID: 11707147
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis.
Augustine M; Horwitz MJ
Curr Osteoporos Rep; 2013 Dec; 11(4):400-6. PubMed ID: 24078470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
